VKA-based Regimen

DRUG2 trials

Sponsors

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company, Daiichi Sankyo

Conditions

Atrial Fibrillation

Phase 3

Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation

CompletedNCT02942576

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyAtrial Fibrillation

Start: 2017-03-21End: 2018-09-24Updated: 2019-09-23

Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)

CompletedNCT02943785

Daiichi SankyoAtrial Fibrillation

Start: 2017-03-21End: 2021-02-28Updated: 2022-03-24

Related Papers

Patient-Reported Outcomes Using Win Ratio Analysis: A Post Hoc Analysis from the Randomized ENVISAGE-TAVI AF Trial.

2025-12-30

Edoxaban Dose Adjustment and Age-Associated Outcomes in Patients With Atrial Fibrillation Post-Transcatheter Aortic Valve Replacement.

2025-11-19

Comparing Major Gastrointestinal Bleeding in Patients Receiving Edoxaban Versus Warfarin After Transcatheter Aortic Valve Replacement: Results From the Randomized ENVISAGE‐TAVI AF Trial

Journal of the American Heart Association2025-05-15

Abstract 16781: The Duration of Anticoagulant Treatment and Its Association With HRQoL and Treatment Satisfaction in Patients With AF After TAVR: Results From ENVISAGE-TAVI AF

Circulation2023-11-07

Abstract 15692: Clinical Outcomes in TAVR Patients Receiving Oral Anticoagulation Stratified by Baseline Creatinine Clearance Levels: A Subanalysis of the ENVISAGE-TAVI AF Trial

Circulation2023-11-07

Clinical outcomes in patients receiving oral anticoagulation stratified by the presence of dose reduction criteria and older age: a subanalysis of ENVISAGE-TAVI AF

European Heart Journal2023-11-01

Treatment Satisfaction and Convenience for Patients With Atrial Fibrillation on Edoxaban or Vitamin K Antagonists After Transcatheter Aortic Valve Replacement: A Post Hoc Analysis from the ENVISAGE-TAVI AF Trial

The American Journal of Cardiology2023-10-144 citations

Predictors of All-Cause Mortality After Successful Transcatheter Aortic Valve Implantation in Patients With Atrial Fibrillation

The American Journal of Cardiology2023-09-206 citations

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR

New England Journal of Medicine2021-08-28251 citations

Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement

BMJ Open2021-01-0112 citations

Left Atrial Appendage Closure and TAVR – A Matter of Timing and Patient Selection

Structural Heart2018-09-07

Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial.

2018-08-2949 citations

Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE‐AF study.

Clinical Cardiology2018-04-0111 citations

Analysis of cardiovascular mortality, bleeding, vascular and cerebrovascular events in patients with atrial fibrillation vs. sinus rhythm undergoing transfemoral Transcatheter Aortic Valve Implantation (TAVR)

BMC Cardiovascular Disorders2017-12-0110 citations